Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs

FDA’s focus on the optimal dose for AstraZeneca’s medullary thyroid cancer treatment vandetanib could portend a harder line in ensuring that appropriate dosing for new cancer drugs is established before approval.